In an European Medicines Agency (EMA) public health statement issued by the COVID-19 EMA pandemic Task Force (COVID-ETF), healthcare professionals are reminded that patients receiving chloroquine or hydroxychloroquine for the treatment of COVID-19 should be closely monitored due the risk of serious adverse events.^[@CR1]^

Several observational studies investigating chloroquine or hydroxychloroquine in patients with COVID-19 have reported an increased risk of serious heart disorders including arrhythmias and cardiac arrest.

Healthcare professionals prescribing chloroquine or hydroxychloroquine for COVID-19 should take into account pre-existing heart disorders, uncorrected potassium or magnesium levels, and concomitant use of drugs that cause QT interval prolongation, which increase the risk of arrhythmias which are potentially more severe at higher dosages or in combination with azithromycin, said the EMA. Chloroquine or hydroxychloroquine may also cause hypoglycaemia, liver disorders, seizures, and neuropsychiatric disorders including agitation, confusion, insomnia, psychosis and suicidal ideation, they added.

Clinical trials of chloroquine and hydroxychloroquine in patients with COVID-19 have been suspended or discontinued in some EU countries due to emerging data.

\"While further analyses of available data are being carried out, chloroquine and hydroxychloroquine should only be used in clinical trials for treatment or prophylaxis of COVID-19 or in national emergency use programmes in hospitalised patients under close supervision. It is important that properly designed, randomised clinical trials can be completed, with adjustments as needed, to generate the necessary evidence on benefits and risks of these medicines in COVID-19,\" said the EMA.

**Trials stopped in Denmark**

Five clinical trials in Denmark evaluating the efficacy of hydroxychloroquine for the treatment of COVID-19 have been stopped until further notice because of the risks of serious adverse events, says the Danish Medicines Agency.^[@CR2]^

This follows the reporting of a multinational trial on hydroxychloroquine in *The Lancet*which found no beneficial effects in patients with COVID-19. The mortality rate was increased in these patients and serious heart disorders were reported.

The Danish Medicines Agency may consider resuming clinical trials of hydroxychloroquine in patients with COVID-19 after the safety of the drug for this infection has been established.
